Comparative Pharmacology
Head-to-head clinical analysis: VIGADRONE versus VIMPAT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: VIGADRONE versus VIMPAT.
VIGADRONE vs VIMPAT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Irreversible inhibitor of GABA transaminase (GABA-T), leading to increased brain concentrations of gamma-aminobutyric acid (GABA).
Selective enhancement of slow inactivation of voltage-gated sodium channels, resulting in stabilization of hyperexcitable neuronal membranes and inhibition of repetitive neuronal firing.
Adults: 500 mg orally twice daily, may increase by 500 mg/day every week; maximum 1500 mg twice daily.
Adults: 200 mg oral or IV as a loading dose, followed by 100 mg twice daily (200 mg/day) starting the day after loading. May increase by 50 mg twice daily every week up to 200 mg twice daily (400 mg/day).
None Documented
None Documented
Terminal elimination half-life: 5-7 hours in young adults; 12-15 hours in elderly; therapeutic steady-state achieved within 2-3 days.
Terminal half-life: 13-16 hours (mean ~13 h at steady state); prolonged with renal impairment (CrCl <30 mL/min: ~22 h) and in patients with hepatic impairment (Child-Pugh B: ~17 h; Child-Pugh C: ~22 h).
Renal: 70% unchanged; hepatic metabolism: 20% (primarily via CYP4A7, not CYP450); fecal: <5%.
Renal: ~95% (40% as parent drug, 39% as O-desmethyl metabolite, and ~15% as other minor metabolites); minimal biliary/fecal elimination (less than 1%).
Category C
Category C
Anticonvulsant
Anticonvulsant